Wave Life Sciences (WVE) 10-Q2018 Q1 Quarterly report

Filed: 9 May 18, 5:26pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: added, adjust, adjustment, allele, Alzheimer, amortization, analyzed, approach, ASC, ataxia, autosomal, Bolno, breadth, Bulletin, category, caution, chirality, clarified, Codification, component, constrained, constraint, contingent, counterparty, cumulative, customer, depreciation, developmental, directly, discount, distinct, dominant, enacted, enhance, entity, expansion, expedient, expertise, explain, eye, flow, free, FTE, GGGGCC, header, hedged, hereditary, incremental, injection, input, intact, intravitreal, Investor, irrespective, Keith, language, leaving, legislation, licensee, line, marketplace, measure, measurement, measuring, messenger, modification, mouse, Muscle, ophthalmologic, ophthalmology, original, outset, overcome, package, Parkinson, partner, past, Paul, potency, precursor, predominant, primate, rare, reconciling, recovered, reevaluate, Regnante, repurchase, resolved, reversal, royalty, satisfaction, Spinocerebellar, step, stranded, surrogate, Takeda, thereunto, timeframe, transcript, underlying, undersigned, undue, unexercised, unrecognized, unsatisfied

Removed: advancement, amounted, anniversary, applying, assuming, attract, canceled, capacity, chairman, Classification, commercialized, competitive, complexity, Conversely, convertible, core, declaring, deducting, defective, denominated, deployed, dilute, direct, dollar, economic, establishing, expenditure, final, frame, geographical, hypothetical, impacted, incorporate, incurring, laboratory, lapse, lease, leveraging, limiting, liquidation, locally, located, moiety, noncurrent, outsourcing, ownership, payable, pharmacologic, planned, prospective, restricting, RSU, scalable, select, sensitivity, space, sponsored, stereochemistry, substantially, tracked, transacted, translation, underwriting, unvested, valuation, worldwide, yen

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

WVE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Wave Life Sciences Ltd. (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the quarter ended March 31, 2018 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 9, 2018		/s/ Paul B. Bolno, M.D.
		Paul B. Bolno, M.D.
		President and Chief Executive Officer
		(Principal Executive Officer)

Dated: May 9, 2018		/s/ Keith C. Regnante
		Keith C. Regnante
		Chief Financial Officer
		(Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.